News and Press Releases
Press releases
Theralase Release’s Q322 Interim Financial Statements
Press ReleaseToronto, Ontario – November 29, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activat...
Theralase® Grants Stock Options
Press ReleaseToronto, Ontario – November 21, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated...
Theralase ® Closes Private Placement Equity Financing
Press ReleaseToronto, Ontario – November 17, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated...
Theralase ® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing
Press ReleaseNot for distribution to U.S. news wire services or dissemination in the United States. Toronto, Ontario – October 3, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical st...
Theralase ® Announces Warrant Extension
Press ReleaseToronto, Ontario – September 29, 2022, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo D...
Theralase ® Closes $2.5M Private Placement Equity Financing
Press ReleaseToronto, Ontario – September 22, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activat...
Theralase Release’s Q222 Interim Financial Statements
Press ReleaseToronto, Ontario – August 29, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated...
Theralase Expands Intellectual Property Portfolio?
Press ReleaseToronto, Ontario – June 28, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Ph...
Theralase® Research – One of the Top 10 Most Downloaded Papers
Press ReleaseToronto, Ontario – June 24, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Pho...
Theralase® Phase Ib NMIBC Clinical Study Published
Press ReleaseToronto, Ontario – June 21, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Ph...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
